AKT1 and breast carcinoma: In breast cancer cells, PD-L1 binding with PD-1 induced phosphorylation of AKT and ERK, activating PI3K/AKT and MAPK/ERK pathways, and increased expression of chemotherapy refractory molecule MDR1 [9].